| GPN |
Report |
Adjusted EPS |
BEAT |
pred ~$3.51 vs. cons $3.46 |
MEDIUM |
| GPN |
Report |
Adjusted net revenue |
IN-LINE |
pred ~$3.14B vs. cons $3.16B |
MEDIUM |
| GPN |
Report |
Normalized constant-currency adjusted net revenue growth |
MISS |
pred ~3.7% vs. cons 4.0% |
MEDIUM |
| GPN |
Guide |
Adjusted EPS |
BETTER |
guide ~$13.90 midpoint vs. cons $13.82 (FY2026) |
MEDIUM |
| GPN |
Guide |
Normalized constant-currency adjusted net revenue growth |
LOWER |
guide ~4.5% vs. cons 5.0% (FY2026) |
LOW |
| GPN |
Guide |
Normalized adjusted operating-margin expansion |
UNCHANGED |
guide ~150 bps vs. cons 150 bps (FY2026) |
MEDIUM |
| GPN |
Guide |
Normalized constant-currency adjusted net revenue growth |
LOWER |
guide ~4.8% vs. cons 5.3% (2H2026) |
LOW |
| GPN |
Return |
Day-1 residual (stock − beta × S&P 500) |
-4.5% |
— |
MEDIUM |
| GPN |
Return |
5-day cumulative residual |
-6.0% (FOLLOW-THROUGH) |
A Q2 organic-growth result of ~3.7% vs. 4.0% consensus and a 2H2026 outlook of ~4.8% vs. 5.3% consensus would outweigh an EPS beat; weaker out-period revenue assumptions should pull FY2027 estimates lower after day 1. |
MEDIUM |